- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07056491
Blood Test for Predicting Abdominal Aortic Aneurysm Growth
This important study explores a new blood test that may help doctors predict how fast an abdominal aortic aneurysm (AAA) will grow and when it might become dangerous. An AAA is a bulge in the main blood vessel (aorta) in your belly that can silently grow larger over time. If it gets too big or bursts, it can be life-threatening.
Currently, doctors mainly use ultrasound or CT scans to measure the size of the aneurysm to decide when surgery might be needed. However, size alone doesn't always tell the whole story about how risky an aneurysm is. This research looks at a special protein called REST4 that appears in the blood when muscle cells in the artery wall change their behavior. The study suggests that higher levels of REST4 might mean the aneurysm is growing faster or is more likely to rupture.
The study will follow 70 patients with medium-sized AAAs (3.9-4.9 cm) for 5 years. Researchers will check REST4 levels in the blood and see how they relate to:
- The current size of the aneurysm
- How fast the aneurysm grows over time
- Whether the aneurysm eventually needs surgery or ruptures
- Patient survival rates
If successful, this blood test could give doctors an earlier warning when an aneurysm is becoming dangerous, even before it reaches the traditional size threshold for surgery. This could help personalize treatment plans and potentially save lives by identifying high-risk patients sooner.
Why this research matters:
- AAAs often have no symptoms until they rupture, which is frequently fatal
- About 200,000 people in the U.S. are diagnosed with AAAs each year
- Current monitoring relies heavily on repeated imaging tests
- A simple blood test could make monitoring safer, easier and more precise
- Better risk prediction could help avoid unnecessary surgeries while not missing dangerous aneurysms
For patients, this research represents hope for:
- Fewer surprise ruptures
- More personalized treatment decisions
- Potentially fewer and less frequent imaging tests
- Earlier detection of dangerous changes in their aneurysm
The study is particularly important because it follows patients over 5 years, giving reliable information about how well REST4 predicts long-term outcomes. While more research will be needed after this study, a successful blood test could become part of routine AAA care within the next decade.
This research also highlights how studying basic cellular changes (like how muscle cells in the artery wall behave) can lead to practical tests that improve patient care. The REST4 protein was first discovered in lab studies of aneurysm tissue, showing how laboratory research translates to real-world medical advances.
Upcoming Clinical Trials
-
NCT07941323Not yet recruitingMusculoskeletal Pain | Occupational Diseases
-
NCT07941011Not yet recruitingParotid Cancer | Parotidectomy | Frey's Syndrome | Parotidectomy, Patient-reported Outcomes | Parotid Gland Tumor
-
NCT07942831Not yet recruitingCaregiver Burden | Psychological Distress
-
NCT07943208Not yet recruitingHip Abductor Insufficiency Following Total Hip Arthroplasty
-
NCT07911137Not yet recruitingHypospadias | Ureteropelvic Junction Obstruction
-
NCT07943585Not yet recruitingA Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate VaccinePneumococcal Infectious Disease
-
NCT07942428RecruitingPostoperative Nasal Fibrosis After Rhinoplasty
-
NCT07943377Not yet recruiting
-
NCT07943637Recruiting
-
NCT07941505Not yet recruiting